Risk appeared to be greater in trials testing >1 g\/day dosing<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 13, 2021 (HealthDay News) — Long-term marine omega-3 supplementation is associated with an increased risk for atrial fibrillation (AF), according to a study published online Oct. 6 in Circulation<\/em>.<\/p>\n Baris Gencer, M.D., M.P.H., from Geneva University Hospitals in Switzerland, and colleagues conducted a systematic literature review to identify randomized controlled trials assessing the effects of marine omega-3 fatty acids supplementation on cardiovascular outcomes. The meta-analysis included seven trials (81,210 patients).<\/p>\n The researchers reported that nearly three-quarters of participants (72.6 percent) were enrolled in trials testing \u00e2\u0089\u00a41 g\/day and 27.4 percent in trials testing >1 g\/day of omega-3 fatty acids. The mean age of participants was 65 years, with 39 percent women and an average follow-up of 4.9 years. The meta-analysis showed the use of marine omega-3 fatty acid supplements was associated with an increased risk for AF (2,905; hazard ratio [HR], 1.25), with the risk higher in the trials testing >1 g\/day (HR, 1.49) versus those testing \u00e2\u0089\u00a41 g\/day (HR, 1.12).<\/p>\n “Since the benefit of omega-3 fatty acids also appears to be dose dependent, the associated risk of AF should be balanced against the benefit on atherosclerotic cardiovascular outcomes,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n